قيد المعالجة

الرجاء الانتظار...

الإعدادات

الإعدادات

1. WO2012019168 - ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF

ملاحظة:نص مبني على العمليات الآلية للتعرف الضوئي على الحروف. الرجاء استخدام إصدار PDF لقيمته القانونية

CLAIMS

What is claimed is:

1. A pharmaceutical formulation comprising:

i) an effective amount of a synthetic messenger ribonucleic acid (mRNA) encoding a granulocyte colony-stimulating factor (G-CSF) polypeptide; and

ii) a pharmaceutically acceptable carrier,

wherein i) the mRNA comprises pseudouridine, 5'methyl-cytidine or a combination thereof, or ii) wherein the mRNA does not comprise a substantial amount of a nucleotide or nucleotides selected from the group consisting of uridine, cytidine, and a combination of uridine and cytidine, and wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof.

2. The pharmaceutical formulation of claim 1, wherein the G-CSF polypeptide comprises:

a) the amino acid sequence of SEQ ID NOs: 13 or 14;

b) an amino acid sequence at least 95% identical to SEQ ID NOs: 13 or 14; c) a fragment of SEQ ID NOs: 13 or 14;

d) the amino acid sequence encoded by the nucleic acid of SEQ ID NO: 2 or SEQ ID NO: 17; or

e) the amino acid sequence encoded by a nucleic acid at least 95% identical to SEQ ID NO: 2 or SEQ ID NO: 17.

3. The pharmaceutical formulation of claim 1, further comprising a lipid-based transfection reagent.

4. The pharmaceutical formulation of claim 1, wherein the mRNA lacks at least one

destabilizing element.

5. A kit comprising the pharmaceutical formulation of claim 1 and AMD3100 (1, 1-'[1,4- phenylene-bis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane), in one or more containers, and instructions for use thereof.

6. A pharmaceutical formulation consisting essentially of:

i) an effective amount of a synthetic messenger ribonucleic acid (mRNA) encoding a granulocyte colony-stimulating factor (G-CSF) polypeptide;

ii) a cell penetration agent; and

iii) a pharmaceutically acceptable carrier,

wherein i) the mRNA comprises pseudouridine, 5'methyl-cytidine or a combination thereof, or ii) wherein the mRNA does not comprise a substantial amount of a nucleotide or nucleotides selected from the group consisting of uridine, cytidine, and a combination of uridine and cytidine, and

wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof.

7. A method to obtain progenitor and/or stem cells from a mammalian subject, comprising the steps of: (a) administering to the subject a composition comprising a synthetic messenger ribonucleic acid (mRNA) encoding a granulocyte colony-stimulating factor (G-CSF) polypeptide in an amount effective to mobilize the progenitor and/or stem cells into the peripheral blood of the subject; followed by (b) harvesting the progenitor and/or stem cells.

8. The method of claim 7 wherein the mRNA or a pharmaceutically acceptable salt thereof is administered to the subject in the dosage range of about 1.0 μg/kg- 100 mg/kg of body weight.

9. The method of claim 7, wherein the subject is human.

10. The method of claim 7, wherein the composition is administered to the subject by an intravenous route.

11. The method of claim 7, further comprising the step of administering an effective amount of AMD3100 (1,1 '-[1,4-phenylene-bis(methylene)]-bis-1,4,8,11- tetraazacyclotetradecane) to the subject after administering the composition.

12. The method of claim 11, wherein the composition is administered at least twice but fewer than ten times prior to administering the AMD3100.

13. The method of claim 7, wherein the composition further comprises a synthetic messenger ribonucleic acid (mRNA) encoding i) a macrophage inflammatory protein (MIP) polypeptide or ii) an antibody that prevents EGF binding by EGFR.

14. An improved regimen for mobilizing hematopoietic stem and progenitor cells in a

mammalian subject in need thereof, the regimen comprising an amount of a synthetic messenger ribonucleic acid (mRNA) encoding a G-CSF polypeptide effective to enhance

mobilization of hematopoietic stem cells and progenitor cells (HSPC), and an effective amount of AMD3100 (1,1'-[1,4-phenylene-bis(methylene)]-bis-1,4,8,11- tetraazacy clotetradecane) .

15. A pharmaceutical formulation comprising:

i) an effective amount of a synthetic messenger ribonucleic acid (mRNA) encoding an insulin polypeptide; and

ii) a pharmaceutically acceptable carrier,

wherein i) the mRNA comprises pseudouridine, 5'methyl-cytidine or a combination thereof, or ii) wherein the mRNA does not comprise a substantial amount of a nucleotide or nucleotides selected from the group consisting of uridine, cytidine, and a combination of uridine and cytidine, and

wherein the formulation is suitable for repeated intravenous administration or intramuscular administration to a mammalian subject in need thereof.

16. The pharmaceutical formulation of claim 15, wherein the insulin polypeptide comprises:

a) the amino acid sequence of SEQ ID NOs: 155 or 16;

b) an amino acid sequence at least 95% identical to SEQ ID NOs: 15 or 16; c) a fragment of SEQ ID NOs: 15 or 16;

d) the amino acid sequence encoded by the nucleic acid of SEQ ID NOs: 3 or 4, or SEQ ID NOs: 2 lor 23; or

e) the amino acid sequence encoded by a nucleic acid at least 95% identical to SEQ ID NOs: 3 or 4, or SEQ ID NOs: 21 or 23.

17. The pharmaceutical formulation of claim 15, further comprising a lipid-based

transfection reagent.

18. A method of regulating carbohydrate and lipid metabolism in a mammalian subject in need thereof, comprising the step of: (a) administering to the subject a composition comprising a synthetic messenger ribonucleic acid (mRNA) encoding an insulin polypeptide in an amount effective to regulate carbohydrate and lipid metabolism in the subject.